-
公开(公告)号：US20060235222A1
公开(公告)日：2006-10-19
申请号：US10542621
申请日：2004-01-20
申请人： Michael Bell , Konstantinos Gavardinas , Douglas Gernert , Timothy Grese , Prabhakar Jadhav , Peter Lander , Mitchell Steinberg
发明人： Michael Bell , Konstantinos Gavardinas , Douglas Gernert , Timothy Grese , Prabhakar Jadhav , Peter Lander , Mitchell Steinberg
IPC分类号： A61K31/506 , C07D413/02 , C07D417/02 , C07D409/02 , C07D405/02 , C07D403/02
CPC分类号： C07D401/06 , C07D209/08 , C07D209/10 , C07D333/56 , C07D333/68 , C07D403/06 , C07D405/04 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06 , C07D491/04 , C07F5/003 , C07F5/069 , C07F7/0836
摘要： The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.
摘要翻译： 本发明提供式I化合物或其药学上可接受的盐，药物组合物，其包含有效量的式I化合物与合适的载体，稀释剂或赋形剂的组合，以及用于治疗生理障碍，特别是充血性心脏的方法 包括向其中的患者施用有效量的式I化合物。
-
2.发明申请Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators 失效双环取代的吲哚衍生物类固醇激素核受体调节剂公开(公告)号：US20070185161A1
公开(公告)日：2007-08-09
申请号：US10598330
申请日：2005-02-18
IPC分类号： A61K31/4709 , C07D403/04 , C07D405/04 , C07D409/04 , A61K31/405
CPC分类号： C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D403/10 , C07D405/04 , C07D409/04
摘要： The present invention provides a compound of the formula: Formula (I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, hypertension, and atherosclerosis, comprising administering to a patient in thereof an effective amount of a compound of Formula I. X-16125
摘要翻译： 本发明提供下式的化合物：式（I）; 其药物组合物包含有效量的式I化合物与合适的载体，稀释剂或赋形剂的组合，以及用于治疗生理障碍，特别是充血性心脏病，高血压和动脉粥样硬化的方法，包括施用 对其中的患者有效量的式I化合物。X-16125
-
公开(公告)号：US20070037788A1
公开(公告)日：2007-02-15
申请号：US10576761
申请日：2004-12-08
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/4184 , A61K31/454 , C07D413/14 , C07D405/14 , C07D403/14
CPC分类号： C07D235/26 , C07D405/06 , C07D405/14
摘要： The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐; 药物组合物包含有效量的式（I）化合物与合适的载体，稀释剂或赋形剂的组合; 以及用于治疗生理障碍，特别是充血性心脏病，高血压，类风湿性关节炎或炎症的方法，包括向其中的患者施用有效量的式（I）化合物。
-
![Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators](/abs-image/US/2011/06/28/US07968587B2/abs.jpg.150x150.jpg)
4.发明授权公开(公告)号：US07968587B2
公开(公告)日：2011-06-28
申请号：US12447693
申请日：2007-11-06
申请人： Konstantinos Gavardinas , Jonathan Edward Green , Prabhakar Kondaji Jadhav , Donald Paul Matthews
发明人： Konstantinos Gavardinas , Jonathan Edward Green , Prabhakar Kondaji Jadhav , Donald Paul Matthews
IPC分类号： A61K31/403 , C07D209/60
CPC分类号： C07D209/58
摘要： The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐; 包含式（I）化合物与合适的载体，稀释剂或赋形剂组合的药物组合物; 以及用于治疗生理障碍，特别是骨量减少，骨质疏松症，骨质减少或肌肉质量或强度降低的方法，包括施用式（I）化合物或其药学上可接受的盐。 X-17142。
-
公开(公告)号：US07803814B2
公开(公告)日：2010-09-28
申请号：US10576761
申请日：2004-12-08
申请人： Konstantinos Gavardinas , Jonathan Edward Green , Prabhakar Kondaji Jadhav , Donald Paul Matthews
发明人： Konstantinos Gavardinas , Jonathan Edward Green , Prabhakar Kondaji Jadhav , Donald Paul Matthews
IPC分类号： A61K31/445 , C07D401/14
CPC分类号： C07D235/26 , C07D405/06 , C07D405/14
摘要： The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐; 药物组合物包含有效量的式（I）化合物与合适的载体，稀释剂或赋形剂的组合; 以及用于治疗生理障碍，特别是充血性心脏病，高血压，类风湿性关节炎或炎症的方法，包括向其中的患者施用有效量的式（I）化合物。
-
6.发明申请Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators 有权取代的N-芳基吡咯烷酮作为选择性雄激素受体调节剂公开(公告)号：US20080176864A1
公开(公告)日：2008-07-24
申请号：US11913710
申请日：2006-05-10
IPC分类号： A61K31/506 , C07D207/04 , A61K31/40 , C07D401/04 , A61K31/4439 , A61K31/4245 , A61P15/08 , A61P15/00 , A61P25/24 , C07D413/04 , C07D405/10 , A61K31/4025 , C07D403/04
CPC分类号： C07D207/09 , C07D401/04 , C07D405/06 , C07D413/06 , C07D417/06
摘要： The present invention provides a compound of the Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐; 药物组合物包含有效量的式（I）化合物与合适的载体，稀释剂或赋形剂的组合; 以及用于治疗生理障碍，特别是虚弱，骨质疏松症，骨质减少和男性和女性性功能障碍的方法，其包括向有需要的患者施用有效量的式（I）化合物。
-
7.发明授权Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators 失效双环取代的吲哚衍生物类固醇激素核受体调节剂公开(公告)号：US07728150B2
公开(公告)日：2010-06-01
申请号：US10598330
申请日：2005-02-18
IPC分类号： C07D215/38
CPC分类号： C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D403/10 , C07D405/04 , C07D409/04
摘要： The present invention provides a compound of the formula: Formula (I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, hypertension, and atherosclerosis, comprising administering to a patient in thereof an effective amount of a compound of Formula I. X-16125
摘要翻译： 本发明提供下式的化合物：式（I）; 其药物组合物包含有效量的式I化合物与合适的载体，稀释剂或赋形剂的组合，以及用于治疗生理障碍，特别是充血性心脏病，高血压和动脉粥样硬化的方法，包括施用 对其中的患者有效量的式I化合物。X-16125
-
公开(公告)号：US08227468B2
公开(公告)日：2012-07-24
申请号：US13273302
申请日：2011-10-14
申请人： Gary G. Deng , Konstantinos Gavardinas , Prabhakar Kondaji Jadhav , Euibong Jemes Kim , Matthew Allen Schiffler
发明人： Gary G. Deng , Konstantinos Gavardinas , Prabhakar Kondaji Jadhav , Euibong Jemes Kim , Matthew Allen Schiffler
IPC分类号： A61K31/496 , C07D305/08 , C07D407/12
CPC分类号： C07D407/14 , C07D407/04
摘要： The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders such as rheumatoid arthritis, psoriasis, and lupus comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐。 此外，本发明提供了包含式（I）化合物或其药学上可接受的盐与药学上可接受的稀释剂或载体的药物组合物。 本发明还提供了治疗腹主动脉瘤，斑块不稳定性，动脉粥样硬化或自身免疫疾病如类风湿性关节炎，牛皮癣和狼疮的方法，其包括施用治疗有效量的式（I）化合物或其药学上可接受的盐或 包含式（I）化合物或其药学上可接受的盐和药学上可接受的稀释剂或载体的药物组合物。
-
公开(公告)号：US07994164B2
公开(公告)日：2011-08-09
申请号：US12330539
申请日：2008-12-09
IPC分类号： A61K31/535 , C07D413/14
CPC分类号： C07D405/06 , C07D405/14 , C07D498/04
摘要： The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明提供式（I）的化合物或其药学上可接受的盐; 包含式（I）化合物与合适的载体，稀释剂或赋形剂组合的药物组合物; 以及用于治疗生理障碍，特别是充血性心力衰竭，高血压，糖尿病肾病或慢性肾脏疾病的方法，包括给予式（I）化合物或其药学上可接受的盐。
-
10.发明授权Substituted N-arylpyrrolidines as selective androgen receptor modulators 有权取代的N-芳基吡咯烷酮作为选择性雄激素受体调节剂公开(公告)号：US07807691B2
公开(公告)日：2010-10-05
申请号：US11913710
申请日：2006-05-10
IPC分类号： A61K31/4025 , C07D207/06 , C07D207/08 , C07D207/10
CPC分类号： C07D207/09 , C07D401/04 , C07D405/06 , C07D413/06 , C07D417/06
摘要： The present invention provides a compound of the Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐; 药物组合物包含有效量的式（I）化合物与合适的载体，稀释剂或赋形剂的组合; 以及用于治疗生理障碍，特别是虚弱，骨质疏松症，骨质减少和男性和女性性功能障碍的方法，其包括向有需要的患者施用有效量的式（I）化合物。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.037 秒)